In November 2022, Lusaris Therapeutics made news for its $60 million Series A round. Since then, there has been a curious silence from the company. We...
MindMed has completed dosing of its main Phase 2b clinical trial. The study — investigating LSD for Generalized Anxiety Disorder (GAD) — has dosed...
Crops for 2023 were underwhelming, but things could turn around in 2024. Select Harvests is expecting good output in 2024 ... Read More The post Farmers...
As the digital era transforms, fifth-generation (5G) wireless technology emerges as the linchpin of tomorrow’s connectivity. That represents a colossal...
Microdose is partnering with Concordia for the 2023 Concordia Annual Summit, taking place September 18-20 in New York City. The post Microdose Partners...
The ASX 200 rattled to a 2.2% halt since Monday AM. The Energy sector was decently charged, though, while everything ... Read More The post ASX...
Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly. In fact, I’ve uncovered seven of the top...
AWAKN-P001 Is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for The Treatment of Severe Alcohol Use Disorder...
Local markets are enjoying a gentle uplift this morning, while med-tech EMD builds a warchest to fight PTSD with MDMA. ... Read More The post ASX...
COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced...